Navigation Links
Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Date:3/25/2009

CRANBURY, N.J., March 25 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the issuance on March 10, 2009 of United States Patent No. 7,501,439, titled "Tartrate Salt of Isofagomine and Methods of Use." The patent covers the tartrate salt form of isofagomine, the active ingredient in the Company's investigational drug Plicera(TM) (afegostat tartrate), and its use for the treatment of Gaucher disease. The patent will expire in 2027.

John F. Crowley, President and CEO of Amicus, commented, "The issuance of this patent further strengthens our protection in the United States for Plicera in Gaucher and is one example of our ongoing efforts to establish a comprehensive intellectual property portfolio for our development programs and our pharmacological chaperone technology platform."

Plicera is currently being studied in an ongoing Phase 2 study in patients naive to enzyme replacement therapy. This six-month study is designed to evaluate safety and to demonstrate trends of efficacy, as measured by the standard endpoints in Gaucher disease. Amicus previously reported that enrollment has been completed for the study and the Company expects the results to be available in the third quarter of 2009.

Amicus is developing Plicera as part of a strategic collaboration with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the collaboration, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic d
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... NEW YORK , Aug. 1, 2014 ... Square Capital Management, L.P. today responded to the filing ... AGN ) in California.  The complaint makes baseless ... offer rules.  Allergan,s true purpose in ... shareholders, efforts to call a special meeting.  That purpose ...
(Date:8/1/2014)... Aug. 1, 2014 In the latest call ... sexual dysfunction, more than 60 doctors and leading medical ... letter questioning the Food and Drug Administration,s (FDA) decision ... form of male sexual dysfunction compared with ZERO for ... to act for women by approving the first-ever drug ...
(Date:8/1/2014)... Aug. 1, 2014 In the latest call ... sexual dysfunction, more than 60 doctors and leading medical ... letter questioning the Food and Drug Administration,s (FDA) decision ... form of male sexual dysfunction compared with ZERO for ... to act for women by approving the first-ever drug ...
Breaking Medicine Technology:Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 660+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3
... Reportlinker.com announces that a new market research report ... Drug Markets in Europe ... and the strategies of major pharmaceutical companies ... in Europe remains problematic for the developers, although ...
... Urban League (NUL) and the League of United Latin American ... negotiations and come to an agreement with Walgreens on new ... Americans, especially in diverse and underserved communities, stand to lose ... In an open letter to Express Scripts, Marc H. ...
Cached Medicine Technology:Orphan Drug Markets in Europe 2Orphan Drug Markets in Europe 3Orphan Drug Markets in Europe 4Orphan Drug Markets in Europe 5Orphan Drug Markets in Europe 6Orphan Drug Markets in Europe 7The National Urban League and League of United Latin American Citizens Urge Express Scripts to Reach Agreement with Walgreens 2The National Urban League and League of United Latin American Citizens Urge Express Scripts to Reach Agreement with Walgreens 3
(Date:8/1/2014)... 2014 The evolving healthcare landscape ... pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor ... and resources to enhance patient care and profitability. ... critical issues to give independent pharmacists the tools ... , ThoughtSpot show attendance experienced a nearly 70% ...
(Date:8/1/2014)... Washington, DC (PRWEB) August 01, 2014 ... Mike Thompson (D-CA), Gregg Harper (R-MS), and Peter ... H.R. 5380, the Medicare Telehealth Parity Act of ... "We fully support this effort to improve healthcare ... Linkous, chief executive officer of ATA. "These cost-saving ...
(Date:8/1/2014)... 2014 On Monday, June 30th, the ... Symposium in San Francisco, CA. Now in its fourth ... Marriott Union Square hotel. , “We are excited about ... speed with ACA compliance issues,” Quirk Healthcare Foundation Executive ... provides attendees guidance with NextGen implementation and use, electronic ...
(Date:8/1/2014)... 2014 (HealthDay News) -- Although many parents worry about their ... common choking hazard: food. Such was the case ... after eating a handful of nuts. "At the time, ... the coughing was related to his illness or choking," recalled ... A cashew had become lodged in his windpipe and had ...
(Date:8/1/2014)... August 01, 2014 Over the ... benefited from innovative technologies that have enabled cosmetic ... patient's tooth color. Moreover, the burgeoning elderly population ... age-related tooth ailments. Due to long-term use of ... individuals have demanded dental fillings, veneers and implants. ...
Breaking Medicine News(10 mins):Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... 10 Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today ... results on Monday, April 28, 2008 at approximately,4:00 p.m. ... a,conference call at 4:30 p.m. ET. Henry L. Nordhoff, ... president, finance, and,chief financial officer, will host the call., ...
... provide more on ,how to, than ,how to prevent, ... study says that people surfing the Web for information about ... act rather than offering help and support. , Researchers from ... search terms, one at a time, into each of the ...
... Collaboration Platform is Gaining ... Significant Usage in the Healthcare Vertical, ... market,leader in delivering effective and easy-to-use Web 2.0 ... corporations and,membership organizations, is pleased to announce a ...
... Ensure Union Democracy, OAKLAND, Calif., April ... restore democracy to the nation,s largest union ... which will be,considered at the union,s upcoming ... proposed by members of United Healthcare,Workers-West, SEIU,s ...
... IRIDEX,Corporation (Nasdaq: IRIX ) today reported final financial results ... Revenue for the fourth quarter of 2007 was $14.1 ... fourth quarter of 2006. The,Company,s net loss was $15.8 million ... compared with a loss of $3.8 million or $0.48 per,diluted ...
... dramatically reduced with this method, researchers find , , ... fresh fruits and vegetables can reduce the risk ... all disease-causing bacteria, new research shows. , The ... reviewed by the U.S. Food and Drug Administration, ...
Cached Medicine News:Health News:Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call 2Health News:Suicide Data on Web Mostly Not Preventive 2Health News:Healthcare Sector Benefits from Online Community 2Health News:UHW Unveils Proposals for SEIU Convention 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:Irradiation Almost Erases Risk of Food Poisoning 2Health News:Irradiation Almost Erases Risk of Food Poisoning 3Health News:Irradiation Almost Erases Risk of Food Poisoning 4
... offers a complete line of flowmeters, available in oxygen, ... available in a variety of calibrations to best suit ... to the gas in use, the Amvex Flowmeter is ... the U with I. For Power Take-Off add PT ...
... Amvex offers a complete line of flowmeters, available in ... all available in a variety of calibrations to best ... specific to the gas in use, the Amvex Flowmeter ... replace the U with I. For Power Take-Off add ...
... complete line of flowmeters, available in oxygen, air, heliox ... a variety of calibrations to best suit your application. ... gas in use, the Amvex Flowmeter is a user ... with I. For Power Take-Off add PT to the ...
0-3.5 LPM Oxygen Flowmeter with Ohmeda male inlet...
Medicine Products: